The AVID-CC trial will test the anti-tumor necrosis factor (anti-TNF) drug and will be aimed at treating people in the community, especially in care homes. It will enroll up to 750 patients from community care settings throughout the UK.
The AVID-CC trial will test the anti-tumor necrosis factor (anti-TNF) drug and will be aimed at treating people in the community, especially in care homes. It will enroll up to 750 patients from community care settings throughout the UK.
